1. Home
  2. PRMB vs COGT Comparison

PRMB vs COGT Comparison

Compare PRMB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primo Brands Corporation

PRMB

Primo Brands Corporation

N/A

Current Price

$21.41

Market Cap

6.9B

Sector

N/A

ML Signal

N/A

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

N/A

Current Price

$37.76

Market Cap

6.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRMB
COGT
Founded
1955
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PRMB
COGT
Price
$21.41
$37.76
Analyst Decision
Buy
Buy
Analyst Count
10
15
Target Price
$28.80
$33.50
AVG Volume (30 Days)
5.3M
1.5M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,871,000.00
Revenue This Year
$2.31
N/A
Revenue Next Year
$3.55
$1,180.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.36
$3.72
52 Week High
$35.85
$43.73

Technical Indicators

Market Signals
Indicator
PRMB
COGT
Relative Strength Index (RSI) 60.32 49.13
Support Level $15.21 $36.08
Resistance Level $22.96 $41.02
Average True Range (ATR) 0.78 1.63
MACD 0.06 -0.14
Stochastic Oscillator 63.06 41.26

Price Performance

Historical Comparison
PRMB
COGT

About PRMB Primo Brands Corporation

Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: